Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that leads to inflammation, demyelination and ultimately axonal degeneration. In most cases, it is preceded by its precursor, clinically isolated syndrome (CIS) with conversion rates to clinically definite MS (CDMS) of roughly 20-75%. Neurologists are therefore faced with the challenge of initiating a disease-modifying therapy (DMT) as early as possible to favorably influence the course of the disease. During the past 20 years, a multitude of drugs have been incorporated into our therapeutic armamentarium for MS and CIS. Choosing the right drug for an individual patient is complex and should be based not only on the drug's overall efficacy to prevent disease progression but also its specific adverse reaction profile, the severity of individual disease courses and, finally, patient compliance in order to adequately weigh associated risks and benefits. Here, we review the available data on the efficacy, safety and tolerability of DMTs tested for CIS and discuss their value regarding a delay of progression to CDMS.

Department of Neurology Medical Faculty Heinrich Heine University Moorenstrasse 5 40225 Düsseldorf Germany

Department of Neurology University Hospital and Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Zobrazit více v PubMed

Lancet Neurol. 2014 Mar;13(3):247-56 PubMed

N Engl J Med. 2010 Feb 4;362(5):416-26 PubMed

J Neuroimmunol. 2013 Sep 15;262(1-2):113-20 PubMed

Front Neurol. 2018 Aug 29;9:718 PubMed

Brain. 2008 Mar;131(Pt 3):808-17 PubMed

J Neurochem. 2017 Apr;141(2):296-304 PubMed

Eur J Neurol. 2008 Sep;15(9):916-21 PubMed

Trends Pharmacol Sci. 2007 Jul;28(7):342-9 PubMed

Mult Scler. 2009 Jun;15(6):728-34 PubMed

Nat Med. 2000 Dec;6(12):1399-402 PubMed

JAMA Neurol. 2015 Dec;72(12):1433-41 PubMed

Brain. 2006 Mar;129(Pt 3):584-94 PubMed

J Neurol. 2009 Jul;256(7):1061-6 PubMed

Ann Neurol. 1983 Mar;13(3):227-31 PubMed

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):285-294 PubMed

Nat Rev Neurol. 2017 Jan;13(1):25-36 PubMed

Mult Scler. 2013 Dec;19(14):1878-86 PubMed

Mult Scler. 2013 Jul;19(8):1074-83 PubMed

Ann Neurol. 2007 Jun;61(6):504-13 PubMed

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):621-625 PubMed

Neurology. 1998 Mar;50(3):701-8 PubMed

Neurology. 1993 Apr;43(4):655-61 PubMed

Mult Scler. 2003 Jun;9(3):260-74 PubMed

Lancet. 2009 Oct 31;374(9700):1503-11 PubMed

Neurology. 2007 Mar 6;68(10):779-81 PubMed

N Engl J Med. 2017 Jun 1;376(22):2122-2133 PubMed

Neurology. 2019 Feb 12;92(7):e733-e741 PubMed

Nature. 2002 Nov 7;420(6911):78-84 PubMed

Lancet Neurol. 2012 Feb;11(2):157-69 PubMed

Mult Scler. 2010 Apr;16(4):450-4 PubMed

Arch Neurol. 2009 Jul;66(7):841-6 PubMed

Lancet. 2014 Jun 28;383(9936):2213-21 PubMed

Ann Neurol. 2005 Dec;58(6):840-6 PubMed

Lancet. 2018 Apr 21;391(10130):1622-1636 PubMed

Neurology. 2006 Oct 10;67(7):1242-9 PubMed

Mult Scler. 2013 Feb;19(2):188-98 PubMed

Lancet. 2001 May 19;357(9268):1576-82 PubMed

Mult Scler. 2018 May;24(6):721-727 PubMed

Mult Scler. 2017 Dec;23(14):1820-1821 PubMed

Lancet Neurol. 2018 Feb;17(2):162-173 PubMed

Lancet Neurol. 2012 Jan;11(1):22-4 PubMed

Neurology. 2010 Jun 15;74(24):2004-15 PubMed

Mult Scler. 2015 Jul;21(8):1013-24 PubMed

Lancet Neurol. 2014 Mar;13(3):257-67 PubMed

Neurology. 2012 Apr 10;78(15):1171-8 PubMed

Ann Neurol. 2011 Feb;69(2):292-302 PubMed

Neurology. 2014 Jul 15;83(3):278-86 PubMed

Mult Scler. 2015 Oct;21(11):1443-52 PubMed

J Neurol Neurosurg Psychiatry. 2009 Mar;80(3):292-6 PubMed

Mult Scler. 2011 May;17(5):578-93 PubMed

Eur J Neurol. 2006 Jul;13(7):700-22 PubMed

Eur J Neurol. 2017 May;24(5):703-712 PubMed

Lancet Neurol. 2017 Aug;16(8):591-600 PubMed

Mult Scler. 2016 Aug;22(9):1163-73 PubMed

Ann Neurol. 2001 Jul;50(1):121-7 PubMed

Brain. 2010 Jul;133(Pt 7):1914-29 PubMed

Mult Scler. 2008 Nov;14(9):1191-8 PubMed

Lancet Neurol. 2009 Nov;8(11):987-97 PubMed

Ann Neurol. 2002 Apr;51(4):481-90 PubMed

Mult Scler. 2018 Oct;24(12):1594-1604 PubMed

J Pharm Pract. 2018 Oct;31(5):481-488 PubMed

J Neurol. 2012 Nov;259(11):2401-13 PubMed

N Engl J Med. 2017 Aug 24;377(8):789 PubMed

Neurology. 1995 Jul;45(7):1268-76 PubMed

J Immunol. 2004 Jan 15;172(2):1273-86 PubMed

Mult Scler. 2016 Jun;22(7):893-900 PubMed

Ther Adv Neurol Disord. 2008 Sep;1(2):125-41 PubMed

Ann Neurol. 2007 Apr;61(4):288-99 PubMed

Mult Scler. 2008 Apr;14(3):314-24 PubMed

Brain. 2010 Jul;133(Pt 7):1900-13 PubMed

J Immunol. 2005 May 1;174(9):5630-5 PubMed

Mult Scler. 2012 Oct;18(10):1466-71 PubMed

Mult Scler. 2010 Jul;16(7):848-54 PubMed

J Exp Med. 2003 Mar 17;197(6):725-33 PubMed

Lancet. 2007 Aug 4;370(9585):389-97 PubMed

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9 PubMed

J Neurol. 2008 Apr;255(4):480-7 PubMed

PLoS One. 2014 Jan 30;9(1):e86663 PubMed

Neurology. 2006 Feb 28;66(4):576-8 PubMed

Neurology. 2012 Jan 31;78(5):309-14 PubMed

Neurology. 1999 Oct 12;53(6):1184-90 PubMed

J Neurol. 2014 Mar;261(3):490-9 PubMed

Clin Ther. 2003 Nov;25(11):2865-74 PubMed

Ann Neurol. 1996 Mar;39(3):285-94 PubMed

Lancet. 1996 Jun 22;347(9017):1728-30 PubMed

Lancet Neurol. 2017 Mar;16(3):189-199 PubMed

Mult Scler Relat Disord. 2014 May;3(3):364-71 PubMed

Neurology. 1993 Apr;43(4):662-7 PubMed

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 01;2(6):e158 PubMed

N Engl J Med. 2011 Oct 6;365(14):1293-303 PubMed

Neurology. 2006 Mar 14;66(5):678-84 PubMed

Brain. 2002 Oct;125(Pt 10):2202-12 PubMed

Mult Scler. 2012 Jan;18(1):72-81 PubMed

J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):909-14 PubMed

Lancet Neurol. 2011 Aug;10(8):691-701 PubMed

Brain. 2002 Jun;125(Pt 6):1297-308 PubMed

Brain. 2003 Apr;126(Pt 4):770-82 PubMed

Arch Neurol. 2012 Feb;69(2):183-90 PubMed

Neurology. 2016 Sep 06;87(10):978-87 PubMed

CNS Drugs. 2015 Apr;29(4):277-91 PubMed

Lancet Neurol. 2014 Oct;13(10):977-86 PubMed

Mult Scler. 2017 Dec;23(14):1818-1819 PubMed

Ann Clin Transl Neurol. 2018 Aug 15;5(10):1154-1162 PubMed

Neurology. 2008 Oct 28;71(18):1390-5 PubMed

Brain. 2004 Apr;127(Pt 4):844-50 PubMed

J Neurol Neurosurg Psychiatry. 2008 Nov;79(11):1236-44 PubMed

N Engl J Med. 2000 Sep 28;343(13):898-904 PubMed

Mult Scler J Exp Transl Clin. 2017 Oct 09;3(4):2055217317732802 PubMed

Lancet Neurol. 2012 Jan;11(1):33-41 PubMed

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126-9 PubMed

Brain. 1997 Jun;120 ( Pt 6):1085-96 PubMed

Multiple sclerosis: time for early treatment with high-efficacy drugs